|
WO2021067506A1
|
|
Methods of treating conditions related to the s1p1 receptor
|
|
WO2020146529A1
|
|
Methods of treating conditions related to the s1p1 receptor
|
|
WO2020112880A1
|
|
Methods of treating conditions related to the s1p1 receptor
|
|
WO2020072824A1
|
|
Methods for the treatment of scleroderma
|
|
WO2020051378A1
|
|
Compounds useful in the treatment of autoimmune and inflammatory disorders
|
|
AU2019280822A1
|
|
Methods of treating conditions related to the S1P1 receptor
|
|
WO2019222764A1
|
|
Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
|
|
CN111699189A
|
|
Modulators of beta-3 adrenergic receptors useful for the treatment or prevention of heart failure and disorders associated therewith
|
|
JOP20180111A1
|
|
Modulators of the beta-3 adrenergic receptoruseful for the treatment or prevention of disorders related thereto
|
|
US2020368190A1
|
|
Methods of treatment
|
|
EP3641887A1
|
|
Compounds and methods for treatment of nafld and nash
|
|
WO2018208848A1
|
|
Compounds and methods for treatment of visceral pain
|
|
WO2018208847A1
|
|
Compounds and methods for treatment of pain from inflammatory bowel disease
|
|
EP3589274A1
|
|
Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
|
|
CN110545848A
|
|
Compounds and methods for treating inflammatory bowel disease with extra-intestinal manifestations
|
|
CN110520124A
|
|
For treating the Compounds and methods for of primary biliary cholangitis
|
|
AU2017357759A1
|
|
Methods of treating PAH with combinations of ralinepag and other agents
|
|
CN109952301A
|
|
5-HT2C receptor stimulating agent and composition and application method
|
|
MA44037A1
|
|
Beta 3 adrenergic receptor modulators useful in the treatment or prevention of disorders associated therewith
|
|
WO2017180528A1
|
|
Methods of treatment with selective cb2 receptor agonists
|
